Enliven Therapeutics Raises $400M in Public Offering

By Ahmed Jamerson • Saturday, June 13 10:51 • Permanent Link

Enliven Therapeutics priced an upsized public offering of 8,933,334 shares of common stock at $37.50 a share, plus pre-funded warrants to buy up to 1,733,333 shares at $37.499 each.

The company expects gross proceeds of about $400.0 million before underwriting discounts, commissions and other expenses. If the underwriters exercise their 30-day option in full, Enliven could sell up to an additional 1,600,000 shares at the public offering price.

The company is selling all of the shares and warrants itself. The offering is expected to close on or about June 15, 2026. The market has reacted to these announcements by moving the company's shares 14.3% to a price of $46.13. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.